IXC 6.67% 8.0¢ invex therapeutics ltd

Ann: Invex Granted Key European Patent for Exenatide, page-11

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 795 Posts.
    lightbulb Created with Sketch. 45
    As @arkangel256 has said, I don't think management is particularly concerned with short term fluctuations in the share price. They are fully funded for at least 1 phase III trial and once that is finished they will be looking for a buyout.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.